Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05013723 · ClinicalTrials.gov registry record
Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome
A clinical trial, sponsored by Intermountain Health Care.
- Completed
- Registry status
- 260
- Enrollment target
NCT05013723: Completed study, sponsored by Intermountain Health Care.
NCT05013723 is a clinical trial that has completed, run by Intermountain Health Care. The registered enrollment target is 260 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05013723 has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- 260 participants
- Enrollment target
Study Summary
Use the Intermountain real-world MAb-treatment registry and control group to prospectively evaluate PACS symptoms at least 60 days after initial COVID-19 diagnosis.
Primary Outcome
Post-acute COVID-19 symptom score (out of 60)
Interventions
- OTHER Surveys
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2022-12-16 |
What the finished NCT05013723 record still lists
NCT05013723 is an observational study that tracks outcomes without assigning an intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Surveys is the first listed.
NCT05013723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05013723 about?
NCT05013723 is a clinical study titled "Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome". Use the Intermountain real-world MAb-treatment registry and control group to prospectively evaluate PACS symptoms at least 60 days after initial COVID-19 diagnosis.
What is the current status of trial NCT05013723?
This trial is currently completed. The enrollment target is 260 participants. The study started on 2021-08-30. Estimated completion is 2022-12-16.
What interventions are being tested in trial NCT05013723?
The interventions under investigation include: Surveys (OTHER).
Who is sponsoring clinical trial NCT05013723?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI